Sugi Predict

Sugi Predict / Compounds / SCHEMBL3368531

SCHEMBL3368531

SCHEMBL3368531

COc1ccc(NS(=O)(=O)Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.66
▸ CA2 P00918 1/20 0.66
▸ LMNA P02545 3/20 0.56
▸ GAA P10253 3/20 0.56
▸ MAPK1 P28482 3/20 0.56
▸ ALDH1A1 P00352 6/20 0.53
▸ PGR P06401 2/20 0.53
▸ MAPT P10636 3/20 0.52
▸ NPC1 O15118 2/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ THRB P10828 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ HPGD P15428 1/20 0.50
▸ PLAU P00749 1/20 0.49
▸ PKM P14618 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11708669 0.83 CA1 (0.70) CA1CA2LMNAGAAMAPK1
SCHEMBL171658 0.81 LMNA (0.79) CA1CA2LMNAGAAMAPK1
SCHEMBL19997244 0.80 CA1 (0.61) CA1CA2LMNAGAAMAPK1
1,4-Dimethoxybenzene SCHEMBL5960077 0.79 CA1 (0.65) CA1CA2GAAMAPK1ALDH1A1
SCHEMBL1645328 0.79 CA1 (1.00) CA1CA2LMNAGAAMAPK1
SCHEMBL11350891 0.79 CA1 (0.66) CA1CA2LMNAGAAMAPK1
SCHEMBL21033853 0.79 CA1 (0.66) CA1CA2LMNAGAAMAPK1
SCHEMBL9215868 0.79 CA1 (0.66) CA1CA2LMNAGAAMAPK1
SCHEMBL29380088 0.79 CA1 (0.66) CA1CA2LMNAGAAMAPK1
SCHEMBL15116359 0.79 PTPN1 (0.73) CA1CA2LMNAGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220024891-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2022-01-27 — — US disclosed
EP-3890715-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER The Board Of Regents Of The University Of Texas System (US) 2021-10-13 — — EP disclosed
WO-2020117972-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-06-11 — — WO disclosed
EP-1303503-B1 ANILINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-01-27 — — EP disclosed
US-7507730-B2 Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-24 — — US disclosed
US-7507730-B2 Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-24 — — US disclosed
US-7507730-B2 Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-24 — — US disclosed
EP-1436291-B1 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA SA (FR) 2009-01-14 — — EP disclosed
EP-1311475-B1 AMINOCYCLOHEXANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-08-06 — — EP disclosed
US-7335687-B2 2,3-Oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. (US) 2008-02-26 — — US disclosed
EP-1311475-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-05-21 — — EP disclosed
EP-1303503-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 — — EP disclosed
WO-2003024967-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA S.A. (FR) 2003-03-27 — — WO disclosed
US-20030004156-A1 Dihydroindole and tetrahydroquinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-01-02 — — US disclosed
WO-2002050041-A1 DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-27 — — WO disclosed
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-04-18 — — US disclosed
US-20020038025-A1 Analine derivatives as OSC inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-03-28 — — US disclosed
WO-2002014267-A1 NOVEL AMINOCYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-02-21 — — WO disclosed
WO-2002006189-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — WO disclosed
US-5866587-A HYDROXAMIDE DERIVATIVES OF FUSED PIPERIDINE DERIVATIVES ADIR ET COMPAGNIE (FR) 1999-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024891-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER APC, VHL, KRAS CA1 4511/4885CA2 4515/4885LMNA 3039/4885
US-20030004156-A1 Dihydroindole and tetrahydroquinoline derivatives CYP46A1, LSS, CYP51A1 CA1 2837/4885CA2 2617/4885LMNA 3715/4885
US-20020038025-A1 Analine derivatives as OSC inhibitors LSS, CYP51A1, CYP46A1 CA1 1870/4885CA2 3023/4885LMNA 2799/4885
US-20020045777-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 CA1 2475/4885CA2 2022/4885LMNA 2735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.